

Clinical Oversight Review Board (CORB) Criteria for Prescribing Mirvetuximab soravtansine (Elahere)

Notes:

- Mirvetuximab soravtansine can cause severe ocular adverse reactions. In clinical trials, ocular adverse reactions occurred in over half of patients.
- Premedication as well as lubricating and ophthalmic topical steroid eye drops during mirvetuximab soravtansine treatment are recommended.

Formulary **mirvetuximab soravtansine (Elahere)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria:

- Prescribed by a hematologist or oncologist
- Age greater than or equal to 18 years
- Diagnosis of high-grade serous epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
- Molecular profiling with high expression of folate receptor alpha (FR α), defined as greater than or equal to 75% of tumor cells staining with 2+ intensity
- Patient has received at least 1 and no more than 3 systemic treatments for ovarian, fallopian tube, or primary peritoneal cancer
- Patient has experienced progression of ovarian, fallopian tube, or primary peritoneal cancer within 6 months after receiving platinum-based chemotherapy